Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

2.57
-0.0200-0.77%
Post-market: 2.600.0300+1.17%18:26 EDT
Volume:1.62M
Turnover:4.25M
Market Cap:393.21M
PE:-3.52
High:2.72
Open:2.61
Low:2.55
Close:2.59
52wk High:4.54
52wk Low:1.66
Shares:153.00M
Float Shares:115.00M
Volume Ratio:0.55
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7307
EPS(LYR):-1.8036
ROE:-118.82%
ROA:-23.29%
PB:3.73
PE(LYR):-1.42

Loading ...

Editas slips amid pressure on gene-editing sector after Anthropic update

TIPRANKS
·
Sep 24

Editas Medicine Raised to Buy from Neutral by Guggenheim

Dow Jones
·
Sep 23

Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

MT Newswires Live
·
Sep 23

Top Premarket Gainers

MT Newswires Live
·
Sep 15

Editas Medicine EVP, Chief Medical Officer Daniel Ory Files Initial Beneficial Ownership Statement

Reuters
·
Sep 10

Editas Grants New CMO Daniel Ory Stock Options for 950,000 Shares at USD 3.03 Each

Reuters
·
Sep 09

Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Dow Jones
·
Sep 09

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Dow Jones
·
Sep 08

Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer

THOMSON REUTERS
·
Sep 08

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Editas Medicine Files $400 Million Mixed Shelf

MT Newswires Live
·
Sep 01

Editas Medicine files $400M mixed securities shelf

TIPRANKS
·
Sep 01

Editas Medicine - May Offer up to $400 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Sep 01

Acrivon Therapeutics Names Michaela Levin Chief Business Officer

Reuters
·
Aug 31

Editas Medicine Initiated at Buy by Ladenburg Thalmann

Dow Jones
·
Aug 18

Ladenburg Thalmann Initiates Editas Medicine at Buy With $6 Price Target

MT Newswires Live
·
Aug 18

Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06